CS
FATE icon

Credit Suisse’s Fate Therapeutics FATE Stock Holding History

Credit Suisse’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-128,864
Closed -$273K – 3088
2023
Q3 		$273K Sell
128,864
-46,813
-27% -$155K ﹤0.01% 2959
2023
Q2 		$836K Buy
175,677
+28,284
+19% +$156K ﹤0.01% 2509
2023
Q1 		$840K Sell
147,393
-865,912
-85% -$5.22M ﹤0.01% 2438
2022
Q4 		$10.2M Sell
1,013,305
-2,187
-0.2% -$41.1K 0.01% 926
2022
Q3 		$22.8M Buy
1,015,492
+10,343
+1% +$299K 0.03% 618
2022
Q2 		$24.9M Sell
1,005,149
-4,552
-0.5% -$126K 0.03% 615
2022
Q1 		$39.1M Buy
1,009,701
+11,210
+1% +$434K 0.03% 540
2021
Q4 		$58.4M Sell
998,491
-16,211
-2% -$919K 0.03% 561
2021
Q3 		$60.1M Buy
1,014,702
+6,919
+0.7% +$543K 0.03% 572
2021
Q2 		$87.5M Buy
1,007,783
+1,176
+0.1% +$94.8K 0.05% 430
2021
Q1 		$83M Buy
1,006,607
+247,113
+33% +$23.7M 0.04% 475
2020
Q4 		$69.1M Buy
759,494
+14,289
+2% +$887K 0.03% 562
2020
Q3 		$29.8M Sell
745,205
-56,989
-7% -$1.99M 0.02% 825
2020
Q2 		$27.5M Buy
802,194
+108,778
+16% +$3.24M 0.02% 791
2020
Q1 		$15.4M Sell
693,416
-155,985
-18% -$3.94M 0.01% 964
2019
Q4 		$16.6M Buy
849,401
+3,798
+0.4% +$60.3K 0.01% 1134
2019
Q3 		$13.1M Buy
845,603
+118,238
+16% +$2.27M 0.01% 1158
2019
Q2 		$14.8M Buy
727,365
+661,778
+1,009% +$11.9M 0.01% 1091
2019
Q1 		$1.15M Buy
65,587
+10,608
+19% +$167K ﹤0.01% 2779
2018
Q4 		$705K Buy
54,979
+30,001
+120% +$418K ﹤0.01% 3062
2018
Q3 		$407K Sell
24,978
-8,218
-25% -$97.2K ﹤0.01% 3400
2018
Q2 		$376K Buy
33,196
+15,354
+86% +$169K ﹤0.01% 3555
2018
Q1 		$174K Buy
17,842
+6,612
+59% +$63.3K ﹤0.01% 3726
2017
Q4 		$69K Sell
11,230
-17,237
-61% -$76.9K ﹤0.01% 3885
2017
Q3 		$112K Buy
+28,467
New +$96.8K ﹤0.01% 4075
2017
Q2 		– Sell
-12,372
Closed -$56K – 3862
2017
Q1 		$56K Buy
+12,372
New +$45.3K ﹤0.01% 3739

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Credit Suisse's FATE Position: Q4 2023 in Review

Credit Suisse sold out of Fate Therapeutics (FATE) in Q4 2023, closing a stake of 128,864 shares — an estimated $273K sold.

Credit Suisse first reported a position in FATE in Q1 2017 and held it in 26 quarters. The position peaked at $87.5M in Q2 2021. 159 funds tracked by Wall St. Rank hold FATE as of Q4 2023.

  • Credit Suisse reported no remaining Fate Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Credit Suisse sold 128,864 Fate Therapeutics shares in Q4 2023, an estimated $273K.
  • Credit Suisse first reported a position in Fate Therapeutics in Q1 2017 and held it in 26 quarters.
  • Credit Suisse's Fate Therapeutics position peaked at $87.5M in Q2 2021.
  • 159 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2023.

Based on Credit Suisse's 13F filing for Q4 2023, filed 8 Feb 2024.